ATE210943T1 - Ophthalmologisches abgabesystem - Google Patents

Ophthalmologisches abgabesystem

Info

Publication number
ATE210943T1
ATE210943T1 AT95923983T AT95923983T ATE210943T1 AT E210943 T1 ATE210943 T1 AT E210943T1 AT 95923983 T AT95923983 T AT 95923983T AT 95923983 T AT95923983 T AT 95923983T AT E210943 T1 ATE210943 T1 AT E210943T1
Authority
AT
Austria
Prior art keywords
ophthalmological
delivery system
delivery
formulations
alginate
Prior art date
Application number
AT95923983T
Other languages
English (en)
Inventor
Smadar Cohen
Esther Lobel
Original Assignee
Teva Pharma
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Univ Ben Gurion filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE210943T1 publication Critical patent/ATE210943T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT95923983T 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem ATE210943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26229494A 1994-06-20 1994-06-20
PCT/US1995/007789 WO1995035073A1 (en) 1994-06-20 1995-06-19 Ophthalmic delivery system

Publications (1)

Publication Number Publication Date
ATE210943T1 true ATE210943T1 (de) 2002-01-15

Family

ID=22996942

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923983T ATE210943T1 (de) 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem

Country Status (6)

Country Link
US (1) US5776445A (de)
EP (1) EP0777451B1 (de)
AT (1) ATE210943T1 (de)
DE (1) DE69524772D1 (de)
IL (1) IL114193A (de)
WO (1) WO1995035073A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106819A (en) * 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
FR2777189B1 (fr) * 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
FR2779953B1 (fr) * 1998-06-22 2000-08-11 Codif International Sa Procede d'elaboration d'un produit cosmetique destine a proteger la peau contre les agressions resultant de la pollution de l'air ambiant
US6730691B1 (en) * 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005521690A (ja) * 2002-02-22 2005-07-21 ファルマシア・コーポレーション ゴム系を含む眼科用製剤
EP2130541A3 (de) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Verfahren zur Behandlung oder Vorbeugung von Autoimmunerkrankungen mit 2,4-Pyrimidindiaminverbindungen
MXPA05011896A (es) * 2003-05-05 2006-05-25 Univ Ben Gurion Preparaciones polimericas reticuladas inyectables y sus usos.
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
WO2005066337A2 (en) * 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
KR20070001970A (ko) * 2004-02-26 2007-01-04 보오슈 앤드 롬 인코포레이팃드 알기네이트 점탄성 조성물, 사용 방법 및 팩키지
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US20070004672A1 (en) * 2005-07-01 2007-01-04 Dharmendra Jani Long lasting alginate dry eye, related methods of manufacture and methods of use
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CA2673137C (en) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
US20080153908A1 (en) * 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
WO2008088612A1 (en) * 2006-12-20 2008-07-24 Bausch & Lomb Incorporated Method of stimulating the production of mucin in the eye of a patient
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
WO2008082948A2 (en) * 2006-12-29 2008-07-10 Bausch & Lomb Incorporated Ophthalmic alginate composition related methods of manufacture and methods of use
MX2009011801A (es) * 2007-05-04 2009-11-13 Baush & Lomb Inc Composiciones para reducir, aminorar, tratar o evitar afeccion de ojo seco y metodos para elaboracion y uso de las mismas.
WO2008137826A2 (en) * 2007-05-07 2008-11-13 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20110046033A1 (en) * 2008-01-31 2011-02-24 Jinzhong Zhang Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
US9096819B2 (en) 2008-01-31 2015-08-04 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
US9481856B2 (en) * 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
RU2011100108A (ru) * 2008-06-12 2012-07-20 Новартис АГ (CH) Гелеобразующие in situ системы для пролонгированной доставки на переднюю часть глаза
CA2736380C (en) * 2008-09-15 2013-05-28 Bausch & Lomb Incorporated Compositions comprising polymers having amino sugar units and methods of making and using same
US20100087550A1 (en) 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
CA2746810C (en) 2008-12-30 2017-03-14 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
PT2389372E (pt) 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
EP2396070A4 (de) 2009-02-12 2012-09-19 Incept Llc Wirkstofffreisetzung mit hydrogel-plugs
CN102470135A (zh) 2009-07-28 2012-05-23 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
SI2563771T1 (sl) 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
CN103201280B (zh) 2010-07-28 2016-08-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
BR112013011830B1 (pt) 2010-11-13 2022-03-15 Innocrin Pharmaceuticals, Inc Composto inibidor de metaloenzima, composição que compreende o dito composto, bem como uso do mesmo para tratar uma doença ou transtorno relacionado à metaloenzima
EP2651905B1 (de) 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Metalloenzymhemmerverbindungen
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
EP3682896A1 (de) 2011-04-28 2020-07-22 University of Southern California Aus menschlichen myeloiden suppressorzellen gewonnene krebsmarker
KR101912850B1 (ko) 2011-06-19 2018-10-30 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
EP2721022B1 (de) 2011-06-19 2019-03-06 Viamet Pharmaceuticals (NC), Inc. Metalloenzymhemmerverbindungen
EA025266B1 (ru) 2011-06-23 2016-12-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
DK2788343T3 (en) 2011-12-11 2018-06-14 Viamet Pharmaceuticals Nc Inc METALLOENZYMIN INHIBITOR COMPOUNDS
CN104136427B (zh) 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
WO2013142038A2 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
BR112015031253B1 (pt) 2013-06-13 2021-09-28 Orgenesis Ltd. Método para produção de uma população de células transdiferenciada
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
EP3294212B1 (de) 2015-05-12 2023-10-25 Incept, LLC Arzneimittelabgabe aus hydrogelen
ES2811136T3 (es) 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物
ES2940911T3 (es) 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
CA3040526A1 (en) 2016-10-26 2018-05-03 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
PT3532470T (pt) 2016-10-26 2023-02-28 Rigel Pharmaceuticals Inc Derivados de oxazol para uso como inibidores de irak e método para a sua preparação
EP3547836B1 (de) 2016-11-30 2024-08-21 University of Southern California Perillylalkohol-3 bromopyruvat-konjugat und verfahren zur behandlung von krebs
CN110691598A (zh) 2016-12-29 2020-01-14 赛列尼蒂治疗(百慕大)有限公司 金属酶抑制剂化合物
EP3562306A4 (de) 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. Metalloenzym-inhibitor-verbindungen
SG11201911256UA (en) 2017-05-08 2020-01-30 Orgenesis Ltd Transdifferentiated cell populations and methods of use thereof
WO2019006126A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
SI3788045T1 (sl) 2018-05-03 2023-07-31 Rigel Pharmaceuticals, Inc. Zaviralne spojine RIP1 in postopki njihove izdelave in uporabe
SG11202010915XA (en) 2018-05-03 2020-12-30 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
JP2022543843A (ja) 2019-08-08 2022-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
AU2020335903A1 (en) 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
EP4025575A1 (de) 2019-09-06 2022-07-13 Rigel Pharmaceuticals, Inc. Rip1-inhibitorverbindungen und verfahren zu ihrer herstellung und verwendung
MX2022002718A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos.
WO2021092336A1 (en) 2019-11-07 2021-05-14 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 inhibitory compounds
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
US20230312568A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
IT1203814B (it) * 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
WO1989008446A1 (en) * 1988-03-09 1989-09-21 Snow Brand Milk Products Co., Ltd. Suspended-release preparation prepared by using alginic acid
FR2645439B1 (fr) * 1989-04-07 1991-06-21 Oreal Procede de preparation de capsules d'alginate(s) particulierement adaptees a un usage cosmetique, appareil pour sa mise en oeuvre et composition cosmetique contenant lesdites capsules
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
CA2064160C (en) * 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions

Also Published As

Publication number Publication date
IL114193A0 (en) 1995-10-31
EP0777451B1 (de) 2001-12-19
IL114193A (en) 2000-02-29
DE69524772D1 (de) 2002-01-31
EP0777451A1 (de) 1997-06-11
EP0777451A4 (de) 1998-06-10
US5776445A (en) 1998-07-07
WO1995035073A1 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
DE69524772D1 (de) Ophthalmologisches abgabesystem
BR0014203A (pt) Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
AU6185398A (en) Charged lipids and uses for the same
FI970788A0 (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DE69728678T2 (de) Hydrokolloid-wundgel
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
HU9603200D0 (en) Use of gel formulations as dressing agents
AR004168A1 (es) Composicion farmaceutica liquida vertible acuosa
ATE284996T1 (de) Papiertuch enthaltend antivirale wirkstoffe die hautfreundlich sind
ATE240094T1 (de) Ophthalmische zusammensetzungen in form wässriger gele
ATE272389T1 (de) Verwendung einer lacrophyl zubereitung in augentropfen, die therapeutisch wirksame komponenten enthalten
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
SE9403905D0 (sv) New formulations
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
SE9302203D0 (sv) Composition for ophthalmic use
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
MX9302272A (es) Retinoides solubles en agua.
KR950700685A (ko) 최음제로서 사용되는 요드화수소산(use of hydriodic acid as an aphrodisiac)
ES512751A0 (es) "procedimiento para la preparacion de un colirio antiseptico para afecciones oculares".
ES2132642T3 (es) Concentrados acuosos para suspension de endosulfan.
ECSP961924A (es) Formulacion pesticida
UA29890C2 (uk) Краплі для очей "вінісан"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties